Ac-225 User Group Meeting Introduction by Dr. Eva Birnbaum, Los Alamos National Laboratory
Below we have compiled information from our 2021 Isotope User Meetings including the recording of each meeting and PDFs of the presentations. To access the recordings, click the links below.
2021 Isotope User Group Meetings - Video Recordings
Actinium-225 Users Group Meeting Presentations
Brookhaven National Laboratory
University of California at Berkeley
Developing New Tools to Facilitate the End-Use of Ac-225 by Dr. Rebecca Abergel, the University of California at Berkeley
University of Saskatchewan
Ac-225 and B-213 for Radioimmunotherapy of Cancer, Infections, and Beyond by Dr. Ekaterina Dadachova, University of Saskatchewan
Fusion Pharmaceuticals
![Preliminary Dosimetry Results from a First-in-Human Phase 1 Study Evaluating the Efficacy and Safety of [Ac-225]-FPI-1434 in Patients with IGF-1R Expressing Solid Tumors by Drs. Jim O'Leary and Thomas Armor, Fusion Pharma](/sites/default/files/2021-09/Pages%20from%20Ac225UsersMeeting_FPX0101Dosimetry_30Jul2021_Fusion_sm.jpg)
Preliminary Dosimetry Results from a First-in-Human Phase 1 Study Evaluating the Efficacy and Safety of [Ac-225]-FPI-1434 in Patients with IGF-1R Expressing Solid Tumors by Drs. Jim O'Leary and Thomas Armor, Fusion Pharma
Weill Cornell Medicine
Dual -Targeting: PSMA by Dr. Neil Bander, Weill Cornell Medicine
Johns Hopkins School of Medicine
Dosimetry & Treatment Planning for Ac-225 and Other Alpha-Emitters by Dr. George Sgouros, Johns Hopkins School of Medicine
Astatine-211 User Group Meeting Presentations
University of Washington
At-211 User Group Meeting 2021 by Drs. Yawen Li and Rob Emery, University of Washington
Duke University
Production and Applications of At-211 at Duke University by Dr. Michael Zalutsky, Duke University
Texas A&M University
Steps Forward in At-211 Production and Chemistry at Texas A&M University by Dr. Lauren McIntosh, Texas A&M University
University of California at Davis
Development of At-211 Production at UC Davis by Dr. Eric Prebys, University of California at Davis
University of Pennsylvania
At-211 Production for Translational Science in Radiotherapy by Dr. Mehran Makvandi, University of Pennsylvania
Lead-212 User Group Meeting Presentations
Oak Ridge National Laboratory
Oak Ridge Ra-24/Pb-212 Generator Production by Dr. Roy Copping, Oak Ridge National Laboratory
Viewpoint Molecular Targeting
Preclinical Evaluation of Pb-212/203 Based Theranostics: Dosimetry and Renal Toxicity by Dr. Mengshi Li, Viewpoint
Univ. of California at Berkeley
A Murine Melanoma Growth Suppression Case Study for Pb-212 by Dr. Rebecca Abergel, University of California at Berkeley
Pacific Northwest Nat. Laboratory
Remotely-Prepared Pb-212/Bi-212 Generator Columns: Process Overview & Early Performance Evaluation by Dr. Matt O'Hara, Pacific Northwest National Laboratory
Copper-67 User Group Meeting Presentations
Argonne National Laboratory
Cu-67 DOE Isotope Program User Group Meeting by Dr. David Rotsch, Argonne National Laboratory
City of Hope Medical Center
City of Hope Experience with Cu-67 by Dr. Jack Shively, City of Hope Medical Center
Boston Children's Hospital
A Possible Theranostic Approach to Treating Metastatic Neuroblastoma by Dr. Alan Packard, Boston Children's Hospital
University of Alabama at Birmingham
Cu-67 Studies at UAB by Dr. Jennifer Bartels, University of Alabama at Birmingham
Clarity Pharmaceuticals
Clarity's Targeted Copper Theranostics (TCT) Platform by Mr. Shaemus Gleason, Clarity Pharmaceuticals
